Artes Medical, which has developed an injectable aesthetic treatment for the permanent correction of wrinkles, lowered the range for its IPO on Tuesday. The company now plans to offer 4.6 million shares at a range of $6-$8, as opposed to the originally proposed $12-$14. Cowen & Company and Lazard are managing the deal.
